GrayMatters Health Overview
GrayMatters Health (GMH) develops digital self-neuromodulation therapeutics for mental disorders to help patients regain agency over their emotion regulation. GMH offers Prism, a noninvasive adjunct therapeutic that utilizes novel neuroscience-based and brain-mechanism-specific biomarkers. The company's first product candidate, Prism for post-traumatic stress disorder (PTSD), is undergoing clinical investigation in five sites across the United States and Israel, to demonstrate its efficacy and safety as an adjunct to standard PTSD treatments. Our first product, Prism for PTSD, was cleared by FDA in March 2023. The novel technology was developed by Professor Talma Hendler and her team at Tel Aviv Sourasky Medical Center and Tel Aviv University.
Cumulative Funding Raised Over Time ($)
$10.0MJan 2022
$13.5MMar 2020
$15.6MMar 2023
Latest News
growth-positive
Israeli startup GrayMatters treats PTSD with avatars
Israeli company GrayMatters, which develops innovative treatments for post-traumatic stress disorder (PTSD), has received approval from the US FDA and Israels Ministry of Health to market its technology. The company uses AI software and an EEG headset device to read biomarker activity in the amygdala, the part of the brain which is overactive in people suffering from PTSD. The treatment is administered during 15 visits each lasting 30 minutes, in which the patients see avatars in front of them that they have to move. The company has raised $20 million to date and has begun initial sales in the US.
CustomersInvestmentPartners
Growth-Positive
GrayMatters Health Receives Investment from European Innovation Council (EIC) Fund
GrayMatters Health (GMH), a developer of digital self-neuromodulation therapies for mental disorders, has received an investment from the European Innovation Council (EIC) Fund. This follows a €2.5M grant awarded to GMH by the EIC in September 2022. The funds will be used for the continued development of GMHs flagship product, Prism for PTSD, a non-invasive digital therapy for post-traumatic stress disorder (PTSD), and for a large-scale study in the EU. The EIC Funds investment was advised by the European Investment Bank (EIB).
InvestmentExpand
GrayMatters Health Awarded €2.5M in Funding from European Innovation Council
growth-positive
GrayMatters Health Closes $10M Round A Funding and Partnership in Japan
GrayMatters Health (GMH), a developer of digital self-neuromodulation therapeutics for mental disorders, has raised $10 million in a Series A funding round. The round was led by Otsuka Medical Devices Co., Ltd. (OMD), and included participation from Joy Ventures, J-Ventures, J-Impact, Marius Nacht, and Joyance Ventures. GMH will use the funds to complete its clinical investigation, obtain regulatory clearance, and launch Prism for PTSD in the United States. Prism is a non-invasive adjunct digital therapeutic that uses machine learning technology to create an Electrical-Finger-Print (EFP) of brain-mechanism-specific biomarkers for the treatment of mental disorders.
Investment
growth-positive
McLean Hospital and GrayMatters Health Awarded a BIRD Foundation Grant to Develop a Digital Therapy for Major Depression Disorder with Anhedonia Symptoms
Digital therapeutics start-up GrayMatters Health and McLean Hospital have been awarded a grant by the BIRD Israel-U.S. Binational Industrial Research and Development Foundation. The grant will fund the development of a novel solution for the therapy of Major Depression Disorder (MDD) based on GrayMatters patented fMRI-to-EEG machine-learning platform, Prism. The treatment aims to help individuals with MDD who are unable to feel pleasure learn how to control and modulate their reward system. The project will also allow GrayMatters to expand its indications from PTSD to depression.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $18.3M |
| Last funding | $2.1M |
| Stage | A |
| Rounds | 4 |
| Investors | 8 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.graymatters-health.com |
Locations
Derech HaAtsma'ut 82, Haifa, Israel
Photos & Videos
1 item(s)
GrayMatters Health Business
Business models
B2G, B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareDigital TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Platforms & InterfacesSoftwareArtificial IntelligenceMachine LearningTags (14)
biomarkersdigital-therapeuticsmedical-devicessaasnon-invasivehospitalsclinicsneurologymental-healthdigital-healthcareartificial-intelligencemachine-learningsoftware-applicationstreatmentsGeographic Markets
AsiaEuropeAmericasJapanGrayMatters Health Financials
$18.3M
Total funding
Undisclosed
Capital raised
$2.1M
Last funding
A
Funding stage
4
Total rounds
8
Investors
Cumulative Funding Raised Over Time ($)
$10.0MJan 2022
$13.5MMar 2020
$15.6MMar 2023
Private Equity Funding
SAFE
Mar 2023
$2.1M
European Innovation Council (Lead)
,
European Investment Bank (EIB)
A Round
Jan 2022
$10M
Otsuka Medical Devices (Lead)
,
Marius Nacht, J-Ventures, Joyance Partners, Corundum Neuroscience, J-Impact Fund
Seed
Mar 2020
$3.5M
Joyance Partners (Lead)
Non-Equity Funding
GrantEvent
Sep 2022
$2.7M
European Innovation Council
GrayMatters Health Lifecycle
Cumulative Funding Raised Over Time
$10.0MJan 2022
$13.5MMar 2020
$15.6MMar 2023
All Events
SAFE
Mar 2023
$2.1M
European Innovation Council (Lead)
,
European Investment Bank (EIB)
A Round
Jan 2022
$10M
Otsuka Medical Devices (Lead)
,
Marius Nacht, J-Ventures, Joyance Partners, Corundum Neuroscience, J-Impact Fund
Seed
Mar 2020
$3.5M
Joyance Partners (Lead)
GrantEvent
Sep 2022
$2.7M
European Innovation Council
GrayMatters Health News
8 articles
growth-positive
Israeli startup GrayMatters treats PTSD with avatars
Israeli company GrayMatters, which develops innovative treatments for post-traumatic stress disorder (PTSD), has received approval from the US FDA and Israels Ministry of Health to market its technology. The company uses AI software and an EEG headset device to read biomarker activity in the amygdala, the part of the brain which is overactive in people suffering from PTSD. The treatment is administered during 15 visits each lasting 30 minutes, in which the patients see avatars in front of them that they have to move. The company has raised $20 million to date and has begun initial sales in the US.
CustomersInvestmentPartners
Growth-Positive
GrayMatters Health Receives Investment from European Innovation Council (EIC) Fund
GrayMatters Health (GMH), a developer of digital self-neuromodulation therapies for mental disorders, has received an investment from the European Innovation Council (EIC) Fund. This follows a €2.5M grant awarded to GMH by the EIC in September 2022. The funds will be used for the continued development of GMHs flagship product, Prism for PTSD, a non-invasive digital therapy for post-traumatic stress disorder (PTSD), and for a large-scale study in the EU. The EIC Funds investment was advised by the European Investment Bank (EIB).
InvestmentExpand
GrayMatters Health Awarded €2.5M in Funding from European Innovation Council
growth-positive
GrayMatters Health Closes $10M Round A Funding and Partnership in Japan
GrayMatters Health (GMH), a developer of digital self-neuromodulation therapeutics for mental disorders, has raised $10 million in a Series A funding round. The round was led by Otsuka Medical Devices Co., Ltd. (OMD), and included participation from Joy Ventures, J-Ventures, J-Impact, Marius Nacht, and Joyance Ventures. GMH will use the funds to complete its clinical investigation, obtain regulatory clearance, and launch Prism for PTSD in the United States. Prism is a non-invasive adjunct digital therapeutic that uses machine learning technology to create an Electrical-Finger-Print (EFP) of brain-mechanism-specific biomarkers for the treatment of mental disorders.
Investment
growth-positive
McLean Hospital and GrayMatters Health Awarded a BIRD Foundation Grant to Develop a Digital Therapy for Major Depression Disorder with Anhedonia Symptoms
Digital therapeutics start-up GrayMatters Health and McLean Hospital have been awarded a grant by the BIRD Israel-U.S. Binational Industrial Research and Development Foundation. The grant will fund the development of a novel solution for the therapy of Major Depression Disorder (MDD) based on GrayMatters patented fMRI-to-EEG machine-learning platform, Prism. The treatment aims to help individuals with MDD who are unable to feel pleasure learn how to control and modulate their reward system. The project will also allow GrayMatters to expand its indications from PTSD to depression.
PartnersInvestment
growth-positive
https://www.jpost.com/jpost-tech/bird-to-invest-6m-in-joint-us-israel-innovation-projects-674225
The BIRD Foundation has announced collaborations between US and Israeli companies for joint product development in various technological sectors. The collaborations include Cyberint Technologies and Secure Systems Innovation Corporation, YonaLink and Trialjectory, GrayMatters Health and McLean Hospital Corporation, Over-Sat and MIL-SAT, Sensifree and the Cleveland Clinic, and Skillreal and Siemens DI. The projects will receive grants from BIRD and private sector funding, bringing the total value of all projects to $13m. To date, BIRD’s total investment in joint projects is over $370m.
PartnersInvestment
growth-positive
GrayMatters Health Wins Awards for its Innovative Technology for the Treatment of Mental Disorders
GrayMatters Health, a digital therapeutics start-up, has won a series of international awards for its innovative medical technology for treating mental disorders such as PTSD. The company was one of the top eight to be awarded the 2021 Nature Spinoff Prize, sponsored by Nature and the Merck Group. It was also selected by the HITLAB Breakthrough Alliance (BTA), which will allow GrayMatters Health to work with HITLAB to verify its solution with additional providers and US-based health insurance companies. The company also won First Place in the 2021 SelectUSA Investor Summit Medtech track.
CustomersPartners
growth-positive
Beyond the Pill: a startup reimagines mental health
GrayMatters Health, an Israel-based startup, is developing digital therapeutics for mental disorders. The companys product, Prism for PTSD, uses a machine learning computational model to reproduce the fMRI signal of the amygdala using EEG in real time. This allows patients to learn how to downregulate their amygdala activity, which can lead to clinical improvement in mental disorders such as PTSD. The company aims to work alongside traditional methods to improve clinical outcomes, rather than replace them. GrayMatters Health is planning to expand its portfolio beyond PTSD and venture into the German market.
CustomersExpand
GrayMatters Health Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 30 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
GrayMatters Health Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515916781 |
| Crunchbase | graymatters-health |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-03-24T00:00:00.000Z |
| Created | 2020-03-25T00:00:00.000Z |
| Claimed | Yes |